Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regress-HFpEF: CAP-1002 in HFpEF
NCT02941705Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2017
- Primary completion
- Apr 2023
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of deramiocel in heart failure with preserved ejection fraction (HFpEF), sponsored by Cedars-Sinai Medical Center. Started Jul 2017; status: completed.
02
Drugs
deramiocel
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02941705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941705.